Fernando Doñate
About Fernando Doñate
Fernando Doñate is the Executive Director at BeiGene and a Consultant in oncology at FD Consulting in California. He has extensive experience in translational medicine and oncology research, having held various leadership roles in multiple biotech companies.
Title and Current Roles
Fernando Doñate serves as the Executive Director at BeiGene. In addition, he is a consultant in oncology for FD Consulting based in California, United States.
Education and Academic Background
Fernando Doñate holds a BS/MS in Chemistry/Biology from Universidad Complutense de Madrid. He further advanced his studies with a PhD in Chemistry/Biology from the University of Missouri-Kansas City.
Previous Executive Experience
Fernando Doñate previously held the position of Vice President of Translational Medicine at Adicet Bio, Inc for eight months in Redwood City, California (2022-2023). Earlier, he served as Vice President of Biology at Zentalis Pharmaceuticals for three years in San Diego (2019-2022). His leadership roles also include Vice President of Research at Targazyme for six months in Carlsbad, and Biotech Consultant roles at Meditope and BCN Biosciences for eight months in the Greater Los Angeles Area.
Industry Contributions
Fernando Doñate has contributed significantly to oncology research. He was involved in developing Gilteritinib, approved in 2018, and played a major role in the development of Enfortumab vedotin, from discovery to Phase 3 clinical trials, leading to its approval in 2019. He has authored 40 manuscripts and contributed to several issued patents and patent applications. His portfolio includes participation in 11 Investigational New Drug (IND) applications and 19 clinical trials focusing on solid tumors and hematological malignancies.
Leadership and Research Collaborations
Fernando Doñate has directed interdisciplinary groups of up to 20 people in various research and development projects. He has extensive experience in recruiting and collaborating with research and clinical Key Opinion Leaders (KOL) and Contract Research Organizations (CRO). Additionally, he is skilled in evaluating external in-licensing opportunities for oncology research and development.